Company intelligence / Profile preview
Aowita
Suzhou, Jiangsu, Chinaaowita.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aowita is a biotechnology company focused on the development of mRNA-based vaccines and therapeutics. Utilizing a proprietary lipid nanoparticle (LNP) delivery system, the company aims to address unmet medical needs in infectious diseases, oncology, and rare conditions. Aowita's research emphasizes the optimization of mRNA sequences and delivery efficiency to enhance the safety and efficacy of its candidates. The company is headquartered in Suzhou, China, and operates within the rapidly growing domestic mRNA sector. Their pipeline includes candidates for respiratory viruses and various solid tumors.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- mRNA-based drugsLipid nanoparticle delivery therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Aowita.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aowita.